However, in the phase III GOLD trial, adding PARP inhibitor olaparib to second-line paclitaxel treatment in patients with advanced gastric cancer showed no statistically significant improvement in OS in the whole study population or in the ATM-negative subgroup [94]. This evidence concerns the gene ATM and gastric cancer.